JP2016528233A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016528233A5 JP2016528233A5 JP2016532164A JP2016532164A JP2016528233A5 JP 2016528233 A5 JP2016528233 A5 JP 2016528233A5 JP 2016532164 A JP2016532164 A JP 2016532164A JP 2016532164 A JP2016532164 A JP 2016532164A JP 2016528233 A5 JP2016528233 A5 JP 2016528233A5
- Authority
- JP
- Japan
- Prior art keywords
- apo
- range
- solution
- guhcl
- concentration
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 claims 19
- 102000005666 Apolipoprotein A-I Human genes 0.000 claims 16
- 108010059886 Apolipoprotein A-I Proteins 0.000 claims 16
- 229960000789 guanidine hydrochloride Drugs 0.000 claims 9
- PJJJBBJSCAKJQF-UHFFFAOYSA-N guanidinium chloride Chemical compound [Cl-].NC(N)=[NH2+] PJJJBBJSCAKJQF-UHFFFAOYSA-N 0.000 claims 9
- 238000009472 formulation Methods 0.000 claims 8
- 239000000203 mixture Substances 0.000 claims 8
- 150000002632 lipids Chemical class 0.000 claims 6
- 238000010438 heat treatment Methods 0.000 claims 4
- 238000002360 preparation method Methods 0.000 claims 4
- 241000700605 Viruses Species 0.000 claims 3
- 238000001914 filtration Methods 0.000 claims 2
- 230000002779 inactivation Effects 0.000 claims 2
- 239000002244 precipitate Substances 0.000 claims 2
- NRHMKIHPTBHXPF-TUJRSCDTSA-M sodium cholate Chemical group [Na+].C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC([O-])=O)C)[C@@]2(C)[C@@H](O)C1 NRHMKIHPTBHXPF-TUJRSCDTSA-M 0.000 claims 2
- 239000004094 surface-active agent Substances 0.000 claims 2
- 241000125945 Protoparvovirus Species 0.000 claims 1
- 238000004220 aggregation Methods 0.000 claims 1
- 230000002776 aggregation Effects 0.000 claims 1
- 238000007865 diluting Methods 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 244000309711 non-enveloped viruses Species 0.000 claims 1
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 claims 1
- 239000011148 porous material Substances 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP13179755.7 | 2013-08-08 | ||
| EP13179755 | 2013-08-08 | ||
| PCT/AU2014/000790 WO2015017888A1 (en) | 2013-08-08 | 2014-08-08 | Contaminant removal method |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016528233A JP2016528233A (ja) | 2016-09-15 |
| JP2016528233A5 true JP2016528233A5 (enExample) | 2017-08-31 |
| JP6530394B2 JP6530394B2 (ja) | 2019-06-12 |
Family
ID=48948309
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016532164A Active JP6530394B2 (ja) | 2013-08-08 | 2014-08-08 | 混入物除去方法 |
Country Status (12)
| Country | Link |
|---|---|
| US (3) | US10087235B2 (enExample) |
| EP (2) | EP3030578B1 (enExample) |
| JP (1) | JP6530394B2 (enExample) |
| KR (1) | KR102437202B1 (enExample) |
| CN (2) | CN105452291B (enExample) |
| AU (1) | AU2014305646C1 (enExample) |
| CA (1) | CA2920391C (enExample) |
| DK (1) | DK3030578T3 (enExample) |
| ES (1) | ES2689333T3 (enExample) |
| NZ (1) | NZ631126A (enExample) |
| PL (1) | PL3030578T3 (enExample) |
| WO (1) | WO2015017888A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2014305646C1 (en) * | 2013-08-08 | 2019-01-17 | Csl Limited | Contaminant removal method |
| JP2021513913A (ja) * | 2018-02-19 | 2021-06-03 | バイエル・ヘルスケア・エルエルシーＢａｙｅｒ ＨｅａｌｔｈＣａｒｅ ＬＬＣ | 修正フィルタ膜及び方法 |
| FR3090321B1 (fr) * | 2018-12-21 | 2023-07-14 | Lab Francais Du Fractionnement | Procédé de filtration du fibrinogène |
| US20220175973A1 (en) * | 2019-03-29 | 2022-06-09 | National Institutes for Quantum Science and Technology | Method for producing radiopharmaceutical and radiopharmaceutical |
| CN111351893A (zh) * | 2020-04-28 | 2020-06-30 | 黄河三角洲京博化工研究院有限公司 | 一种利用离子色谱检测盐酸胍样品中胍离子含量的方法 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1335077C (en) * | 1988-02-08 | 1995-04-04 | Henri Isliker | Process for the manufacture of apolipoproteins from human blood plasma or serum |
| US5652339A (en) * | 1993-12-31 | 1997-07-29 | Rotkreuzstiftung Zentrallaboratorium | Method of producing reconstituted lipoproteins |
| SE9500724D0 (sv) * | 1994-06-23 | 1995-02-24 | Pharmacia Ab | Filtrering |
| SE9603068D0 (sv) * | 1996-08-23 | 1996-08-23 | Pharmacia & Upjohn Ab | Process for purifying a protein |
| DE10211632A1 (de) | 2002-03-15 | 2003-10-09 | Aventis Behring Gmbh | Verfahren zur Abtrennung von Viren aus einer Proteinlösung durch Nanofiltration |
| CA2489123C (en) | 2002-06-14 | 2011-03-15 | Centocor, Inc. | Use of a clathrate modifier to promote passage of proteins during nanofiltration |
| WO2009025754A2 (en) * | 2007-08-17 | 2009-02-26 | Csl Behring Gmbh | Methods for purification of alpha-1-antitrypsin and apolipoprotein a-i |
| WO2009036460A2 (en) * | 2007-09-14 | 2009-03-19 | Ambrx, Inc. | Modified human apolipoprotein a-i polypeptides and their uses |
| US10525152B2 (en) * | 2009-10-09 | 2020-01-07 | Signablok, Inc. | Methods and compositions for targeted imaging |
| DK3178481T3 (en) * | 2010-06-30 | 2019-04-08 | Csl Ltd | FORMULATION WITH RECONSTITUTED HIGH DENSITY LIPOPROTEIN AND PROCEDURE FOR PREPARING THEREOF |
| PT2673296T (pt) * | 2011-02-07 | 2019-01-31 | Cerenis Therapeutics Holding Sa | Complexos de lipoproteínas e sua fabricação e utilização |
| US9125943B2 (en) | 2012-11-02 | 2015-09-08 | Csl Limited | Reconstituted HDL formulation |
| DK3004160T3 (da) | 2013-06-05 | 2023-01-23 | Csl Ltd | Fremgangsmåde til fremstilling af apolipoprotein a-i (apo a-i) |
| AU2014305646C1 (en) * | 2013-08-08 | 2019-01-17 | Csl Limited | Contaminant removal method |
| CN104017076B (zh) * | 2014-01-06 | 2016-07-06 | 宁波博泰生物技术有限公司 | 载脂蛋白aⅰ抗血清的制备方法 |
-
2014
- 2014-08-08 AU AU2014305646A patent/AU2014305646C1/en active Active
- 2014-08-08 PL PL14833626T patent/PL3030578T3/pl unknown
- 2014-08-08 US US14/910,424 patent/US10087235B2/en active Active
- 2014-08-08 ES ES14833626.6T patent/ES2689333T3/es active Active
- 2014-08-08 EP EP14833626.6A patent/EP3030578B1/en active Active
- 2014-08-08 CA CA2920391A patent/CA2920391C/en active Active
- 2014-08-08 WO PCT/AU2014/000790 patent/WO2015017888A1/en not_active Ceased
- 2014-08-08 NZ NZ631126A patent/NZ631126A/en not_active IP Right Cessation
- 2014-08-08 CN CN201480044463.6A patent/CN105452291B/zh active Active
- 2014-08-08 EP EP18180083.0A patent/EP3418290A1/en not_active Withdrawn
- 2014-08-08 JP JP2016532164A patent/JP6530394B2/ja active Active
- 2014-08-08 KR KR1020167006225A patent/KR102437202B1/ko active Active
- 2014-08-08 CN CN201910195678.2A patent/CN109701004B/zh active Active
- 2014-08-08 DK DK14833626.6T patent/DK3030578T3/en active
-
2018
- 2018-07-20 US US16/041,239 patent/US10730927B2/en active Active
-
2020
- 2020-07-31 US US16/945,312 patent/US11732028B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012503489A5 (enExample) | ||
| Karkar | Modalities of hemodialysis: quality improvement | |
| JP2019528740A5 (enExample) | ||
| CA2643508C (en) | Process for obtaining high efficiency human albumin for use in detoxification therapy | |
| JP2013500711A5 (enExample) | ||
| WO2008036899A3 (en) | Methods for removing viral contaminants during protein purification | |
| JP2016511238A5 (enExample) | ||
| JPH0348170B2 (enExample) | ||
| ES2226587B1 (es) | Composicion de trombina estable. | |
| CN102580062A (zh) | 人凝血因子Ⅷ与vWF复合物或人凝血因子Ⅷ制剂的干热处理稳定剂 | |
| WO2014075435A1 (zh) | 一种人凝血因子ⅷ的干热处理稳定剂及其用途 | |
| CN109701004B (zh) | 去除污染物的方法 | |
| JPS6237010B2 (enExample) | ||
| WO2012026596A1 (ja) | 熱ヒステリシス活性増加方法、熱ヒステリシス活性の熱失活の低減方法、及び熱ヒステリシス活性増加用組成物 | |
| BR102013018882A2 (pt) | Desativação viral com caprilato | |
| WO2022032368A1 (pt) | Processo de produção de um antígeno, correspondente aos vírus sars-cov-2 inativado, antígeno, correspondente aos vírus sars-cov-2, inativado, composição antigênica, kits e seus usos. | |
| CN103041380B (zh) | 人抗凝血酶制剂干热处理过程中的稳定剂 | |
| CN104804078B (zh) | 人体血清凝血因子ⅷ中的病毒过滤方法 | |
| ES2624245T3 (es) | Procedimiento de preparación de un producto plasmático deplecionado de uno o varios factores trombogénicos | |
| JP2926722B2 (ja) | アルブミン製剤及びその製造方法 | |
| CN105265994A (zh) | 一种有效提高Nisin热稳定性的方法 | |
| JP2009519920A5 (enExample) | ||
| US20240229007A1 (en) | Inactivated vaccines & nucleic acid aptamer therapeutics derived therefrom | |
| JP2011184299A (ja) | モノクローナル抗体を含む製剤の製造方法 | |
| CN106008706A (zh) | 人α1抗胰蛋白酶制品的病毒灭活方法 |